Kivu Bioscience

Kivu Bioscience company information, Employees & Contact Information

Explore related pages

Related company profiles:

As a company focused on rapidly advancing next generation transformative assets, we leverage our expertise to efficiently progress programs to clinical proof of concept. Guided by rigorous science and a commitment to addressing unmet medical needs, our experienced team collaborates with global partners and key opinion leaders to accelerate the delivery of life changing antibody-drug conjugates (ADCs) that aim to conquer cancer.

Company Details

Employees
14
Founded
-
Address
San Francisco, Ca 94105, Us
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
San Francisco, CA
Looking for a particular Kivu Bioscience employee's phone or email?

Kivu Bioscience Questions

News

Kivu Bioscience Appoints Sophia Randolph, M.D., Ph.D., as Chief Medical Officer - FinancialContent

Kivu Bioscience Appoints Sophia Randolph, M.D., Ph.D., as Chief Medical Officer FinancialContent

Kivu Bioscience Presents Preclinical Data for KIVU-107 Demonstrating Potent and Durable Anti-Tumor Activity and a Wide Therapeutic Index at World ADC San Diego 2025 - Business Wire

Kivu Bioscience Presents Preclinical Data for KIVU-107 Demonstrating Potent and Durable Anti-Tumor Activity and a Wide Therapeutic Index at World ADC San Diego 2025 Business Wire

Kivu Bioscience - The Pharma Letter

Kivu Bioscience The Pharma Letter

Precision Oncology Startup Kivu Unveils $92M for More Stable & Durable ADC Cancer Drugs - MedCity News

Precision Oncology Startup Kivu Unveils $92M for More Stable & Durable ADC Cancer Drugs MedCity News

Kivu Bioscience Selects Sterling Pharma Solutions for cGMP Manufacturing of Lead Oncology Antibody-Drug Conjugate KIVU-107 - Business Wire

Kivu Bioscience Selects Sterling Pharma Solutions for cGMP Manufacturing of Lead Oncology Antibody-Drug Conjugate KIVU-107 Business Wire

Kivu Bioscience raises $92 million - The Pharma Letter

Kivu Bioscience raises $92 million The Pharma Letter

Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates - Business Wire

Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates Business Wire

Top Kivu Bioscience Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant